Mesothelioma Treatment Options in 2025: Surgery, Chemo, Immunotherapy

Treatment Overview

Mesothelioma treatment has advanced significantly in recent years. The best treatment plan depends on the type and stage of mesothelioma, cell type, the patient's overall health, and the expertise of the treating team. Treatment is most effective at specialized mesothelioma centers.

Surgery

Surgery is the most aggressive treatment option and is typically only possible in early-stage patients with good overall health. Surgical options for pleural mesothelioma include:

• Pleurectomy/Decortication (P/D) — Removes the pleural lining and visible tumor while preserving the lung. Less invasive than EPP with comparable outcomes in some studies.
• Extrapleural Pneumonectomy (EPP) — Removes the entire affected lung, pleura, part of the diaphragm, and pericardium. More extensive but may achieve better local control.

For peritoneal mesothelioma, cytoreductive surgery (CRS) combined with HIPEC (heated intraperitoneal chemotherapy) has shown remarkable results, with 5-year survival rates of 40–50% in eligible patients.

Chemotherapy

Chemotherapy is the most widely used treatment for mesothelioma, both as a primary treatment and in combination with surgery and immunotherapy.

• Standard first-line regimen: Pemetrexed (Alimta) + cisplatin or carboplatin
• Response rates: approximately 40–45% with pemetrexed-based regimens
• Median survival improvement: approximately 3 months over cisplatin alone
• Bevacizumab (Avastin) may be added to improve outcomes in some patients

Immunotherapy (FDA-Approved 2020, Updated 2025)

The FDA approved nivolumab (Opdivo) + ipilimumab (Yervoy) as a first-line treatment for unresectable pleural mesothelioma in October 2020 — the first new approved treatment in 16 years. As of 2025, this combination remains the standard of care for patients with unresectable pleural mesothelioma, and ongoing trials are investigating next-generation immunotherapy combinations.

• Median overall survival: 18.1 months vs. 14.1 months for chemotherapy
• 2-year survival rate: 41% vs. 27% for chemotherapy
• Particularly effective for non-epithelioid cell types

Other immunotherapy agents being studied include pembrolizumab (Keytruda) and avelumab.

Radiation Therapy

Radiation is rarely used as a standalone treatment for mesothelioma due to the proximity of critical organs. It is most commonly used:

• After surgery to target remaining cancer cells
• As palliative treatment to relieve pain
• As part of trimodality therapy (surgery + chemo + radiation)

Intensity-modulated radiation therapy (IMRT) and proton therapy allow more precise targeting with less damage to surrounding tissue.

Clinical Trials

Clinical trials offer access to cutting-edge treatments not yet widely available. Areas of active research include:

• CAR T-cell therapy targeting mesothelin
• Oncolytic virus therapy
• Gene therapy approaches
• Novel immunotherapy combinations
• Targeted therapy for BAP1-mutated mesothelioma

Multimodal Approach

The most effective treatment for eligible patients combines multiple modalities. A typical trimodality approach for early-stage pleural mesothelioma might include:

• Neoadjuvant chemotherapy (before surgery)
• Surgery (P/D or EPP)
• Adjuvant radiation therapy
• Immunotherapy maintenance

The Multimodal Treatment Approach

The most effective treatment for mesothelioma combines multiple modalities — surgery, chemotherapy, and radiation — in a coordinated approach tailored to the individual patient's disease stage, cell type, and overall health. This multimodal approach, when applied to carefully selected patients at specialized centers, can significantly extend survival and in some cases achieve long-term remission. However, not all patients are candidates for aggressive multimodal therapy, and the treatment plan must be individualized based on a thorough assessment of each patient's specific circumstances.

The decision about which treatment approach is appropriate requires input from a multidisciplinary team that includes a thoracic surgeon, medical oncologist, radiation oncologist, pulmonologist, and other specialists. This is why treatment at a specialized mesothelioma center — where all these specialists work together and see large numbers of mesothelioma patients — is strongly recommended. Centers with dedicated mesothelioma programs have the expertise to offer the full range of treatment options and to select the approach most likely to benefit each individual patient.

Surgical Options

Surgery is the most aggressive treatment option for pleural mesothelioma and is reserved for patients with early-stage disease and good overall health. The two main surgical approaches are extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). EPP involves removing the entire affected lung along with the pleura, diaphragm, and pericardium on the same side. It is the most radical procedure and carries significant risks, but it removes the maximum amount of tumor tissue. P/D involves removing the pleura (the lining of the lung and chest wall) while preserving the lung itself. It is less radical than EPP and has lower operative mortality, but it may leave more residual tumor tissue.

For peritoneal mesothelioma, cytoreductive surgery combined with heated intraperitoneal chemotherapy (HIPEC) has transformed outcomes. This procedure involves removing all visible tumor tissue from the abdominal cavity and then bathing the cavity with heated chemotherapy to kill any remaining cancer cells. At specialized centers, median survival for patients who undergo successful cytoreduction with HIPEC now exceeds 5 years — a dramatic improvement over historical outcomes with chemotherapy alone.

Chemotherapy

Chemotherapy is the standard treatment for patients who are not surgical candidates and is also used in combination with surgery in multimodal approaches. The standard first-line chemotherapy regimen for mesothelioma is pemetrexed (Alimta) combined with cisplatin or carboplatin. This combination was approved by the FDA in 2004 based on clinical trial data showing improved survival compared to cisplatin alone. The typical treatment course involves 4 to 6 cycles administered intravenously every 3 weeks.

Response rates to first-line chemotherapy are approximately 40-45%, meaning that about 40-45% of patients experience significant tumor shrinkage. Median survival with first-line chemotherapy is approximately 12 to 14 months. For patients whose disease progresses after first-line chemotherapy, second-line options include vinorelbine, gemcitabine, and other agents, though response rates to second-line therapy are lower.

Immunotherapy: The 2025 Standard of Care

Immunotherapy is now the cornerstone of first-line mesothelioma treatment in 2025. The combination of nivolumab (Opdivo) and ipilimumab (Yervoy), two immune checkpoint inhibitors, was approved by the FDA in 2020 as a first-line treatment for unresectable pleural mesothelioma based on the results of the CheckMate 743 trial. In that trial, patients treated with nivolumab and ipilimumab had a median overall survival of 18.1 months, compared to 14.1 months with chemotherapy — a significant improvement, particularly for patients with non-epithelioid (sarcomatoid or biphasic) cell types.

Other immunotherapy approaches under investigation include pembrolizumab (Keytruda), avelumab, and various combination regimens. CAR-T cell therapy — which involves engineering a patient's own immune cells to recognize and attack mesothelioma cells — is in early clinical trials. Tumor-treating fields (TTFields), a non-invasive treatment that uses alternating electric fields to disrupt cancer cell division, has shown promise in combination with chemotherapy in clinical trials.

Radiation Therapy

Radiation therapy plays a more limited role in mesothelioma treatment than in many other cancers, primarily because the pleura surrounds the lung and other critical structures that can be damaged by radiation. However, radiation is used in several contexts: as part of multimodal therapy after EPP surgery (to treat the chest cavity after the lung has been removed); for palliative symptom control (to reduce pain from chest wall invasion or to treat specific sites of disease); and to prevent tumor seeding along biopsy or surgical tracts (prophylactic irradiation of procedure sites).

Advances in radiation delivery technology — including intensity-modulated radiation therapy (IMRT) and proton therapy — have improved the ability to deliver high doses of radiation to the tumor while minimizing exposure to surrounding normal tissues. These techniques have expanded the role of radiation in mesothelioma treatment and are available at specialized cancer centers.

Clinical Trials

Clinical trials offer mesothelioma patients access to promising new treatments that are not yet available outside of research settings. Given the poor prognosis of mesothelioma with standard treatments, participation in a clinical trial is often a reasonable option for patients who are not responding to standard therapy or who want access to the latest experimental approaches. ClinicalTrials.gov lists all ongoing mesothelioma clinical trials in the United States and internationally.

When evaluating a clinical trial, patients should consider the phase of the trial (Phase I trials focus on safety; Phase II and III trials evaluate efficacy), the eligibility criteria, the potential benefits and risks, and the practical requirements of participation (such as travel to the trial site). A mesothelioma specialist can help patients identify relevant trials and evaluate whether they are appropriate candidates.

Frequently Asked Questions